Zealand Pharma AS (OCSE:ZEAL)
kr 730 0 (0%) Market Cap: 51.57 Bil Enterprise Value: 43.49 Bil PE Ratio: 0 PB Ratio: 5.83 GF Score: 67/100

Zealand Pharma A/S at Morgan Stanley Global Healthcare Conference Transcript

Sep 12, 2023 / 03:30PM GMT
Release Date Price: kr278 (-0.07%)
Charles David Mabbutt
Morgan Stanley, Research Division - Research Associate

Good morning, everyone. I'm Charlie Mabbutt, Pharmaceuticals equity research analyst and we're delighted to have with us Adam Steensberg, CEO of Zealand. Before we get started, for important disclosures, please see Morgan Stanley research disclosure website at www.morganstanley.com/researchdisclosures, If you have any questions, please reach out to your Morgan Stanley sales representative.

Questions & Answers

Charles David Mabbutt
Morgan Stanley, Research Division - Research Associate

So thanks for being here. So I guess I'll dive straight in and go straight to rare disease. So I guess, firstly, you're in the midst of sort of starting off partnership discussions for Dasiglucagon in CHI. So could you provide, firstly, any update there? And in particular, you had some positive news recently on the acceptance of the first part of the filing. So I guess, how it works with the two parts and

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot